CN102925424A - 溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂 - Google Patents

溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂 Download PDF

Info

Publication number
CN102925424A
CN102925424A CN2012102847193A CN201210284719A CN102925424A CN 102925424 A CN102925424 A CN 102925424A CN 2012102847193 A CN2012102847193 A CN 2012102847193A CN 201210284719 A CN201210284719 A CN 201210284719A CN 102925424 A CN102925424 A CN 102925424A
Authority
CN
China
Prior art keywords
hemolysate
glucose
dithiothreitol
phosphate dehydrogenase
hemolytic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012102847193A
Other languages
English (en)
Inventor
刘和录
吴雄君
窦宇红
华建江
汪奇云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2012102847193A priority Critical patent/CN102925424A/zh
Publication of CN102925424A publication Critical patent/CN102925424A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)

Abstract

本发明提供了一种溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂，所述溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂包括溶血剂及二硫苏糖醇；所述二硫苏糖醇含量介于0.01％至0.25％；所述溶血剂包括：皂素0.01％至0.25％；氯化钠0.60％至1.20％；叠氮化钠0.10％至0.50％。本发明的有益效果在于：在溶血剂中加入二硫苏糖醇可起到保护G-6-PD活性的作用，由于二硫苏糖醇有抗氧化作用，它能保护酶分子上的还原性基团，维持还原性环境，还可防止酶分子间形成二硫键而聚合失活，具有稳定酶的活性作用。

Description

溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂
【技术领域】
本发明涉及一种诊断试剂。 
【背景技术】
葡萄糖-6-磷酸脱氢酶(glucose-6-phosphatase dehydrogenase，G-6-PD)缺乏症是基于红细胞内部对该酶的显著缺乏所致的一种遗传性疾病，俗称蚕豆病，其主要临床表现是溶血性贫血。 
测定红细胞G-6-PD活性是诊断本病的主要手段。因G-6-PD存在于红细胞膜上，不能直接检测，测定红细胞G-6-PD活性时，需将红细胞破坏制备成溶血液方可检测。 
当前，市面上检测红细胞G-6-PD活性的诊断试剂盒，其制备溶血液的方法是通过溶血剂破坏红细胞，将红细胞膜上的G-6-PD溶于这些介质中然后进行检测。由于溶血剂中不含G-6-PD保护剂，故溶血液中的G-6-PD稳定性差，随着溶血液放置时间的延长，该酶的活性快速降低。通过实验发现，溶血液放置1小时，G-6-PD活性下降3.2％-16.1％，平均下降10.1％，溶血液放置2小时，G-6-PD活性下降5.4％-22.8％，平均下降18.1％，这造成了部分本身G-6-PD活性正常的患者检验结果假性偏低而出现误诊误治。 
【发明内容】
本发明的目的在于本发明的目的是提供一种可稳定溶血液中葡萄糖-6-磷酸脱氢酶活性的制剂。 
本发明是通过以下技术方案来实现的： 
所述溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂包括溶血剂及二硫苏糖醇； 
优选地，所述二硫苏糖醇含量介于0.01％至0.25％； 
优选地，所述溶血剂包括：皂素0.01％至0.25％；氯化钠0.60％至1.20％；叠氮化钠0.10％至0.50％。 
本发明的有益效果在于：在溶血剂中加入二硫苏糖醇可起到保护G-6-PD活性的作用，由于二硫苏糖醇有抗氧化作用，它能保护酶分子上的还原性基团，维持还原性环境，还可防止酶分子间形成二硫键而聚合失活，具有稳定酶的活 性作用。 
【具体实施方式】
在一优选实施例中，所述溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂包括： 
皂素：0.10％； 
二硫苏糖醇：0.10％； 
氯化钠：0.80％； 
叠氮化钠：0.35％； 
使用本发明的溶血剂制备20例溶血液放置1小时后，其G-6-PD活性仅下降0.2％-4.1％，平均下降2.3％，比不加保护剂的溶血液平均少下降7.8％，其稳定G-6-PD活性作用明显。 
使用本发明的溶血剂制备20例溶血液放置2小时后，其G-6-PD活性仅下降2.1％-8.6％，平均下降4.4％，比不加保护剂的溶血液平均少下降13.7％，其稳定G-6-PD活性作用非常显著。 
根据上述说明书的揭示和教导，本发明所属领域的技术人员还可以对上述实施方式进行适当的变更和修改。因此，本发明并不局限于上面揭示和描述的具体实施方式，对本发明的一些修改和变更也应当落入本发明的权利要求的保护范围内。此外，尽管本说明书中使用了一些特定的术语，但这些术语只是为了方便说明，并不对本发明构成任何限制。 

Claims (3)

1.一种溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂，其特征在于，包括溶血剂及二硫苏糖醇。
2.根据权利要求1所述溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂，其特征在于，所述二硫苏糖醇含量介于0.01％至0.25％。
3.根据权利要求1所述的溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂，其特征在于，所述溶血剂包括：
皂素0.01％至0.25％；
氯化钠0.60％至1.20％；
叠氮化钠0.10％至0.50％。
CN2012102847193A 2012-08-10 2012-08-10 溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂 Pending CN102925424A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012102847193A CN102925424A (zh) 2012-08-10 2012-08-10 溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012102847193A CN102925424A (zh) 2012-08-10 2012-08-10 溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂

Publications (1)

Publication Number Publication Date
CN102925424A true CN102925424A (zh) 2013-02-13

Family

ID=47640355

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012102847193A Pending CN102925424A (zh) 2012-08-10 2012-08-10 溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂

Country Status (1)

Country Link
CN (1) CN102925424A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1892221A (zh) * 2005-06-29 2007-01-10 希森美康株式会社 含有葡萄糖－6－磷酸脱氢酶(g6pdh)的临床诊断试剂、g6pdh的稳定化方法及g6pdh稳定剂的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1892221A (zh) * 2005-06-29 2007-01-10 希森美康株式会社 含有葡萄糖－6－磷酸脱氢酶(g6pdh)的临床诊断试剂、g6pdh的稳定化方法及g6pdh稳定剂的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BILMEN等: "Antioxidant capacity of G-6-PD-deficient erythrocytes", 《CLINICAL CHIMICA ACTA》 *
唐学恒等: "不同溶血剂导致厚血膜上疟原虫破损情况的观察", 《江苏医药》 *
贾璋林等: "不同溶血方法对葡萄糖262磷酸脱氢酶活性影响的研究", 《国际检验医学杂志》 *

Similar Documents

Publication Publication Date Title
De Simone et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies
Kwon et al. Developmental changes in polyamine levels and synthesis in the ovine conceptus
CN102721684A (zh) 血清中肌酐的二步酶法测定方法及测定试剂
Greaney et al. Time course of changes in enzyme activities and blood respiratory properties of killifish during long-term acclimation to hypoxia
Dave et al. An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isoform II
CA2928442A1 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
CN102507915A (zh) 稳定的乳酸测定液体试剂盒
CN102925424A (zh) 溶血液中葡萄糖-6-磷酸脱氢酶的稳定制剂
Ivanovski et al. Metabolically based liver damage pathophysiology in patients with urea cycle disorders-A new hypothesis
Singh et al. Alterations in some oxidative stress markers in diabetic nephropathy
CN104749122A (zh) 一种血清单胺氧化酶检测试剂盒
CN109298193A (zh) 一种稳定性强的生化检测用液态心肌酶谱复合质控品
Baráth et al. Different pathomechanisms of essential and obesity-associated hypertension in adolescents
Hall et al. The use of dextran sulphate as a blood anticoagulant in biological research
An et al. Activation of pyruvate dehydrogenase by sodium dichloroacetate shifts metabolic consumption from amino acids to glucose in IPEC-J2 cells and intestinal bacteria in pigs
Dahlquist Cerebral utilization of glucose, ketone bodies and oxygen in starving infant rats and the effect of intrauterine growth retardation
Reichle et al. Tryptophan metabolism in phenylketonurics
Ubbink et al. Genetic polymorphism of glutamate-pyruvate transaminase (alanine aminotransaminase): influence on erythrocyte activity as a marker of vitamin B-6 nutritional status
Chaudhary et al. Combined Effect of Low Magnesium and High Sucrose Diet on Magnesium Status and Nitric Oxide Production in Rats.
Young logical variability of serum enzyme activity. Under rigorously defined physiological and analytical conditions it is conceivable that the activity of serum enzymes will prove to be remarkably
CN101762492A (zh) 氨基酸诊断/测定试剂盒及氨基酸浓度测定方法
CN101750320A (zh) 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法
McNulty et al. Hexosamine biosynthetic pathway flux and cardiomyopathy in type 2 diabetes mellitus
CN101750319A (zh) 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法
Chirico et al. Articles in PresS. J Appl Physiol (February 9, 2012). doi: 10.1152/japplphysiol. 01452.2011

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130213

RJ01 Rejection of invention patent application after publication